• 1
    Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H. et al., Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 2010. 363: 411422.
  • 2
    Perez, V. L., Van Parijs, L., Biuckians, A., Zheng, X. X., Strom, T. B. and Abbas, A. K., Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 1997. 6: 411417.
  • 3
    Quezada, S. A., Peggs, K. S., Curran, M. A. and Allison, J. P., CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J. Clin. Invest. 2006. 116: 9351945.
  • 4
    Hodi, F. S., Butler, M., Oble, D. A., Seiden, M. V., Haluska, F. G., Kruse, A., MacRae, S. et al., Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc. Natl. Acad. Sci. USA 2008. 105: 30053010.
  • 5
    Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R. et al., Improved survival with ipilimumab in patients with metastatic melanoma. N. Eng. J. Med. 2010. 363: 711723.
  • 6
    Nocentini, G. and Riccardi, C., GITR: a multifaceted regulator of immunity belonging to the tumor necrosis factor receptor superfamily. Eur. J. Immunol. 2005. 35: 10161022.
  • 7
    Ko, K., Yamazaki, S., Nakamura, K., Nishioka, T., Hirota, K., Yamaguchi, T., Shimizu, J. et al., Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J. Exp. Med. 2005. 202: 885891.
  • 8
    Mitsui, J., Nishikawa, H., Muraoka, D., Wang, L., Noguchi, T., Sato, E., Kondo, S. et al., Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Clin. Cancer Res. 2010. 16: 27812791.
  • 9
    Weber, J., Review: anti CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 2007. 12: 864872.
  • 10
    Boczkowski, D., Lee, J., Pruitt, S. and Nair, S., Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy. Cancer Gene Ther. 2009. 16: 900911.
  • 11
    Shevach, E. M. and Stephens, G. L., The GITR-GITRL interaction: co-stimulation or contrasuppression of regulatory activity? Nat. Rev. Immunol. 2006. 6: 613618.
  • 12
    Ramirez-Montagut, T., Chow, A., Hirschhorn-Cymerman, D., Terwey, T. H., Kochman, A. A., Lu, S., Miles, R. C. et al., Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. J. Immunol. 2006. 176: 64346442.
  • 13
    Shimizu, J., Yamazaki, S., Takahashi, T., Ishida, Y. and Sakaguchi, S., Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance. Nat. Immunol. 2002. 3: 135142.
  • 14
    Cohen, A. D., Schaer, D. A., Liu, C., Li, Y., Hirschhorn-Cymmerman, D., Kim, S. C., Diab, A. et al., Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS One 2010. 5: e10436.
  • 15
    Leach, D. R., Krummel, M. F. and Allison, J. P., Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996. 271: 17341736.
  • 16
    Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P. et al., Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 2003. 100: 83728377.
  • 17
    Beck, K. E., Blansfield, J. A., Tran, K. Q., Feldman, A. L., Hughes, M. S., Royal, R. E., Kammula, U. S. et al., Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J. Clin. Oncol. 2006. 24: 22832289.
  • 18
    Jago, C. B., Yates, J., Olsen Saraiva Cǎmara, N., Lechler, R. I. and Lombardi, G., Differential expression of CTLA-4 among T cell subsets. Clin. Exp. Immunol. 2004. 136: 463471.
  • 19
    Nishikawa, H., Kato, T., Hirayama, M., Orito, Y., Sato, E., Harada, N., Gnjatic, S., Old, L. J. and Shiku, H., Regulatory T cell-resistant CD8+ T cells induced by glucocorticoid-induced tumor necrosis factor receptor signaling. Cancer Res. 2008. 68: 59485954.
  • 20
    Tuyaerts, S., Van Meirvenne, S., Bonehill, A., Heirman, C., Corthals, J., Waldmann, H., Breckpot, K., Thielemans, K. and Aerts, J. L., Expression of human GITRL on myeloid dendritic cells enhances their immunostimulatory function but does not abrogate the suppressive effect of CD4+CD25+ regulatory T cells. J. Leukoc. Biol. 2007. 82: 93105.
  • 21
    Sutmuller, R. P. M., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N. M., Wildenberg, M. E., Allison, J. P., Toes, R. E. M., Offringa, R. and Melief, C. J. M., Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 2001. 194: 823832.
  • 22
    Ribas, A., Comin-Anduix, B. a., Economou, J. S., Donahue, T. R., de la Rocha, P., Morris, L. F., Jalil, J. et al., Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade. Clin. Cancer Res. 2009. 15: 390399.
  • 23
    Maker, A. V., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., Hughes, M. et al., Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J. Immunother. 2006. 29: 455463.
  • 24
    Lee, J., Dollins, C. M., Boczkowski, D., Sullenger, B. A. and Nair, S., Activated B cells modified by electroporation of multiple mRNAs encoding immune stimulatory molecules are comparable to mature dendritic cells in inducing in vitro antigen-specific T-cell responses. Immunology 2008. 125: 229240.
  • 25
    Nair, S., Boczkowski, D., Fassnacht, M., Pisetsky, D. and Gilboa, E., Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. Cancer Res. 2007. 67: 371380.
  • 26
    Dannull, J., Lesher, D.-T., Holzknecht, R., Qi, W., Hanna, G., Seigler, H., Tyler, D. S. and Pruitt, S. K., Immunoproteasome down-modulation enhances the ability of dendritic cells to stimulate anti-tumor immunity. Blood 2007. 110: 43414350.
  • 27
    Banerjee, D. K., Dhodapkar, M. V., Matayeva, E., Steinman, R. M. and Dhodapkar, K. M., Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood 2006. 108: 26552661.